pharma · Colorectal Cancer Metastatic
Dai, Guanghai
Dai, Guanghai is a pharma organization headquartered in CN. Primary therapeutic focus areas include Colorectal Cancer Metastatic. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to t
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Fruquintinib
Phase 2 · small molecule · Colorectal Cancer Metastatic
Fruquintinib for Colorectal Cancer Metastatic is a Phase 2 program (small_molecule) at Dai, Guanghai with 1 ClinicalTrials.gov record(s).
Internal code 2024-415
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dai, Guanghai
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Colorectal Cancer Metastatic
- Status
- active
- Trials
- 1